Evidence map›Paper›PMID 36520331›Full record

ArticleInfectious diseases and therapy2023

Non-invasive Assessment of Liver Fibrosis Regression in Patients with Chronic Hepatitis B: A Retrospective Cohort Study.

Wei Xu, Qiankun Hu, Chong Chen, Weixia Li, Qiang Li, Liang Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. [Predictive role of dynamic changes in liver stiffness measurement for liver-related endpoint events in chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  4. [Non-invasive assessment of liver fibrosis: prioritizing dynamic monitoring and expanding population screening].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  5. [Real-time or dynamic non-invasive liver fibrosis testing for evaluating clinical prognoses and predicting chronic liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Wei Xu *Department of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Qiankun Hu *Department of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Chong Chen *Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Weixia LiDepartment of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Qiang LiDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. liqiang66601@163.com.ORCID http://orcid.org/0000-0003-3831-9001
Liang ChenDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. chenliang@shaphc.org.
Shanghai Public Health Clinical Center · CN

Funding

Shanghai Association for Science and Technology 21S11905600Shanghai Shenkang Hospital Development Center SHDC12020109
6 · The paper itself

Abstract

introductionNon-invasive tests (NITs) have been alternative methods of liver biopsy for the cross-sectional assessment of liver fibrosis in patients with chronic hepatitis B (CHB). However, there are limited data on the longitudinal association between NITs and histological changes of liver fibrosis. This study aimed to evaluate whether NITs can be used to assess liver fibrosis regression (LFR) during anti-HBV treatment.

methodsThis retrospective study included 337 patients with CHB who underwent contemporaneous NITs, such as liver stiffness measurement (LSM), the aspartate aminotransferase to platelet ratio index (APRI), the fibrosis index based on four factors (FIB-4), and the γ-glutamyl transpeptidase to platelet ratio (GPR), and liver biopsy at baseline and followed by a repeated liver biopsy and NITs assessment. The LFR was defined as fibrosis regression by at least one stage assessed by METAVIR scoring system.

resultsThe median interval between the two paired liver biopsy assessment was 31 months (IQR 24-45). At the first liver biopsy, the fibrosis stage was F2 in 159 (47.2%), F3 in 68 (20.2%), and F4 in 110 (32.6%) patients. At the second liver biopsy, the number of patients with fibrosis stages F0-1, F2, F3, and F4 was 102 (30.3%), 106 (31.5%), 63 (18.7%), and 66 (19.6%), respectively. At follow-up liver biopsy, 169 patients (50.1%) had LFR, 128 patients (38.0%) had no change in fibrosis stage, and 40 patients (11.9%) had liver fibrosis progression on histology. A decrease in liver stiffness measurement (LSM) by 25% is the optimal cutoff for predicting LFR. Patients with a 25% or larger decrease in LSM value had more LFR than those with a less than 25% decrease in LSM value (78.1% vs 22.9%, p < 0.001).

conclusionLSM might be used to monitor regression of liver fibrosis during antiviral treatment using nucleos(t)ide analogues (NUCs) in patients with CHB.

Indexed as

Chronic hepatitis BLiver fibrosis regressionLiver stiffness measurementNon-invasive testsRepeated liver biopsy

Identifiers

PMID36520331
PMCPMC9925624
OpenAlexW4311543121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.